Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 6,867

Document Document Title
WO/2016/082583A1
The present invention relates to kinetic resolution of asymmetric catalytic hydrogenation of racemic δ-hydroxy ester and an application thereof. An iridium catalyst of a chiral spiropyridine amidocyanogen phosphin ligand is used; in a c...  
WO/2016/085987A1
The invention relates to a process comprising reacting mevalonic acid, or a solution comprising mevalonic acid, to yield a first product or first product mixture, optionally in the presence of a solid catalyst and/or at elevated temperat...  
WO/2016/080626A2
Described are prodrug conjugates that release a chemotherapeutic agent upon activation by caspase, and methods using such prodrug conjugates to induce apoptosis, amplify apoptosis, and treat cancer.  
WO/2016/066555A1
There is provided polymorphs of ferric maltol. Such forms may be useful in the treatment of iron deficiency with or without anaemia, such as iron deficiency anaemia.  
WO/2016/063990A1
The present invention relates to a compound represented by general formula (1). (The definition of each group in the formula is as described in the specification.) The compound is useful as a prophylactic and/or therapeutic agent for KCN...  
WO/2016/059648A1
The present invention discloses a process for synthesis of chiral 2,4-disubstituted- tetrahydropyran-4-ol and its derivatives having a general formal (I) comprising of asymmetric reaction of an aliphatic aldehyde and a homoallylic alcoho...  
WO/2016/061393A1
Monomethyl and monoethyl fumarate prodrugs, pharmaceutical compositions comprising the monomethyl and monoethyl fumarate prodrugs, and methods of using monomethyl and monoethyl fumarate prodrugs and pharmaceutical compositions for treati...  
WO/2016/057322A1
Provided herein are deuterated compounds and compositions useful in increasing PPAR5 activity. The compounds and compositions provided herein are useful for the treatment of PPAR5 related diseases (e.g., muscular diseases, vascular disea...  
WO/2016/055404A1
The present invention relates to a process for preparation of intermediates (Z,2E)-5-hydroxy-2-methoxyimino-N-methyl-pent-3-enamides from 4-substituted 5-meth-oxyimino-2H-pyran-6-ones and their processing for example to (Z)-5-cyclyloxy-2...  
WO/2016/052069A1
Provided is a thiol compound represented by formula (1); (HS-R1-M1-)nL1 (1). In formula (1), L1 denotes an n-valent organic linking group, n denotes an integer between 3 and 15, M1 denotes -O-, -S-, -N(R2)-, -C(=O)-, -C(=O)-O-, -O-C(=O)-...  
WO/2016/046360A1
The invention relates to the use of isomerically pure or highly isomer-enriched cis- or trans-(2-isobutyl-4-methyl-tetrahydropyran-4-yl)acetate as aroma chemicals. The invention further relates to a method for producing isomerically pure...  
WO/2016/034559A1
The present invention relates to a method for preparing marmycin A and analogues thereof, to novel marmycin A analogues, and also to the use of these compounds as an organelle marker and in pharmacy, in particular as antibiotics, antican...  
WO/2016/034963A1
Compounds of the formula (I) (I), wherein X is O, S, a direct bond or CR16R17; Y is O or S; R1, R2, R3, R4, R5, R6, R7 and R8 for example are hydrogen, halogen, C1-C4alkyl, or a group of formula (II) or (III) (II) (III) provided that eit...  
WO/2016/032148A2
The present invention relates to kartogenin-conjugated chitosan particles with an improved extended release property and biocompatibility. Effects of increases in biocompatibility, chondrogenic differentiation efficiency and staying time...  
WO/2016/028959A1
Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V) and/or a salt thereof, wherein R1 is OH or OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as ...  
WO/2016/019907A1
According to embodiments of present disclosure, a method to produce a compound of Formula (19) is provided. Using this method, the compound of Formula (19) may be produced effectively.  
WO/2016/015596A1
A process of preparing 2, 3-disubstituted-5-oxopyran compounds, comprising cyclizing a compound in the presence of a base and an organic solvent is provided.  
WO/2016/016178A1
The invention relates to the use of a CXCR2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN).  
WO/2016/001396A1
The invention relates to cyclic derivatives of epoxyprostanoids having a lactone ring, in particular to compound (9) and related compounds, and their use as therapeutic agents in the treatment of bacterial infections and inflammation.  
WO/2015/197468A1
The present invention relates to a compound of formula (I) wherein: R1 is C1-C3alkoxy, C1-C2alkoxy-C1-C3alkoxy, C1-C2fluoroalkoxy, ethyl, n-propyl, n-butyl, cyclopropyl or ethynyl; R2 is hydrogen, ethyl, n-propyl, cyclopropyl, vinyl, eth...  
WO/2015/199167A1
Provided is a method for producing a substituted spiropyrido[1,2-a]pyrazine derivative, or a salt thereof, that are useful as anti-HIV agents. Also provided is a production intermediate. Compound [VIII] is obtained by reacting compound [...  
WO/2015/192701A1
An amino pyranoid ring derivative represented by general formula (I), or stereoisomers, pharmaceutically acceptable salts, prodrugs, pharmaceutical compositions containing the derivative and medicinal use thereof in preparing dipeptidyl ...  
WO/2015/187040A1
The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or...  
WO/2015/181186A1
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions con...  
WO/2015/177083A1
The invention belongs to the fields of pharmaceutical industry, and particularly to an improved stereoselective synthesis of intermediate compounds for the preparation of gliflozins, for example canagliflozin or structurally similar glif...  
WO/2015/174695A1
The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate...  
WO/2015/170635A1
This non-ionic surfactant is characterized by being represented by general formula (1). (In general formula (1), R1 is a chain alkyl group optionally containing a branched chain, R2 is a hydrogen atom or an alkyl group, and R3 is a hydro...  
WO/2015/163446A1
The present invention provides a method for producing an imidazole compound represented by formula (I) or a salt thereof, the method being characterized in comprising a step for reacting a compound represented by formula (II) or a salt t...  
WO/2015/163817A1
A fluorophore or conjugated polymer with aggregation-induced emission characteristics useful for drug tracking and delivery, identification and labeling of biological subjects, such as cells or parts of a cell, as well as for imaging, an...  
WO/2015/159103A1
Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are de...  
WO/2015/159233A1
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R2, R3, n, and p are as defined herein, which are active as modulators of retinoid-related orphan re...  
WO/2015/158586A1
The present invention relates to a method for the production of 2-substituted 4-hydroxy-4-methyltetrahydropyrans from the acid-catalyzed reaction of 3-methylbut-3-ene-1-ol with an aldehyde, a stable odoriferous quality being achieved and...  
WO/2015/158584A1
The invention relates to a method for producing 2-substituted 4-methyl-tetrahydropyrans of general formula (I) from starting materials containing at least one 2-substituted 4,4-dimethyl-1,3-dioxane of general formula (II).  
WO/2015/158426A1
The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis ...  
WO/2015/158585A1
The invention relates to a method for producing 2-substituted 4-hydroxy-4-methyl-tetrahydropyrans of general formula (I) from starting materials which contain at least one 2-alkyl-4,4-dimethyl-1,3-dioxane of general formula (II).  
WO/2015/156558A1
The present invention provides a novel 5,6-dihydroergosterol glycoside derivative. The novel 5,6-dihydroergosterol glycoside derivative according to the present invention can be usefully used as an agent for preventing or treating dermat...  
WO/2015/153720A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2015/138969A1
Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subjec...  
WO/2015/137289A1
The present invention pertains to spherical water-dispersible amorphous particles having a particle diameter of 10-990 nm and a PDI of 0.01-0.5, wherein the amorphous particles contain an organic compound having a molecular weight of 50-...  
WO/2015/129412A1
Provided is a liquid crystalline compound that exhibits at least one physical property such as high stability to heat, light, or the like, a high clearing point, a low liquid crystal phase lower limit temperature, a low viscosity, suitab...  
WO/2015/129832A1
The present invention is a radiosensitive resin composition containing: a polymer having a structural unit that contains the group represented by formula (1); and a radiosensitive acid generator. In formula (1), R1 is a substituted or un...  
WO/2015/129860A1
The present invention provides a therapeutic agent useful in the treatment and/or prevention of conditions, including cancer, caused by enhanced OPN production, the therapeutic agent containing a compound represented by the formula (in t...  
WO/2015/126936A1
The invention relates to substituted delta-lactones as well as to processes for synthesizing them, e.g., using fatty acids as starting material.  
WO/2015/117538A1
The present invention relates to a new crystalline form of dapagliflozin represented by formula (I). The crystalline form has a characteristic absorption peak at about 4.318(20.45) in X-ray powder diffraction pattern shown by angle 2 the...  
WO/2015/116786A1
In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another asp...  
WO/2015/110370A1
The present invention relates to compounds of formula wherein R1 is C4-6-cycloalkyl or C4-6-heterocycloalkyl, which are optionally substituted by one or two substituents, selected from hydroxy or lower alkyl; A is phenyl, pyridinyl or pi...  
WO/2015/111529A1
Provided are: a near-infrared absorbing composition which provides a cured film that has high transmittance in the visible light region and exhibits high shielding performance in the near-infrared region; a near-infrared blocking filter;...  
WO/2015/108136A1
The present invention provides: a novel α-substituted glycinamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the compound or the pharmacologically acceptable salt; and a use of the...  
WO/2015/103510A1
Described are RORγ modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided...  
WO/2015/103507A1
Described are RORϒ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions ...  

Matches 351 - 400 out of 6,867